ESTRO 2020 Abstract Book

S495 ESTRO 2020

Conclusion Apart from the IM vessels, the MWT does not cover the IM volumes. If the indication to treat the IM is strong and particularly in the case of positive IM, accurate contouring and contour based planning as well as advanced techniques should be used. PO-0926 Derma-QOL after heparinoid moisturizer for radiation damage in breast-conserving surgery patients J. Kawamori 1 , T. Itasawa 2 , S. Fukushima 3 , R. Ito 2 , C. Haga 2 , H. Yamauchi 4 , K. Sekiguchi 5 1 St Luke International Hospital, Department of Radiation Oncology, Tokyo, Japan ; 2 St Luke’s International Hospital, Department of Radiation Oncology, Tokyo, Japan ; 3 Kumagai Clinic, Radiology, Tokyo, Japan ; 4 St Luke’s International Hospital, Department of Breast Surgery, Tokyo, Japan ; 5 Sonodakai Radiation Oncology Clinic, Radiation Oncology, Tokyo, Japan Purpose or Objective The aim of this study was to evaluate the effect of heparinoid (HP) moisturizer use on quality of life (QOL) in patients with acute radiation skin damage after breast- conserving surgery (BCT-RT). Additional analysis was performed on the effect of dosimetric factors. Material and Methods A randomized controlled trial of a moisturizer group (Group M) and a no-moisturizer group (Group C) to examine whether HP application as moisturizer contributed to improvements in QOL among patients with radiation skin reaction to BCT-RT. A total of 75 patients who received BCT-RT between October 2017 and September 2018 were randomly allocated in our hospital to Group M and Group C. Group M applied HP from the radiation start date twice daily for 7 weeks. QOL was assessed using the Dermatology Life Quality Index (DLQI) at the radiation start date and at Weeks 1, 2, 3, 4, 5 and 7 after the radiation start date. A higher DLQI score indicates a worse quality of life. Radiation treatment was whole-breast irradiation (42.56 Gy in 16 fractions), with added tumor bed boost (10-15 Gy in 4-6 fractions) in 17 cases, according to our hospital protocol. Twenty cases were planned using the field in field method, 52 cases were by tangential breast IMRT. Results 72 cases were analyzed (Group M, 35 cases; Group C, 37 cases). The mean (± standard deviation) DLQI total scores 4 weeks after the start date was 2.063±2.169 in Group M, and 2.233±2.161 in Group C. No significant difference between M and C groups was seen (Mann-Whitney U test, p=0.894). In both groups, the DLQI total score showed no significant change until 2 weeks after the start date, and significantly worsened from 3 weeks to 5 weeks after the start date (Figure 1). No significant difference was seen between groups at 7 weeks after the start date. The difference of DLQI total score tended to be greater in high D max cases from 3 weeks to 5 weeks after the start date . In group C, the difference of DLQI total score was 0.5 in cases with D max <45Gy and 2.313 in cases with D max ≥45Gy, at 4 weeks after the start date (Shapiro-Wilk test, Student- t test p<0.05). In group M, the difference of DLQI total score was 1.25 in cases with D max <45Gy, 1.25 in cases with D max ≥45Gy, at 4 weeks after the start date (Figure 2).

Conclusion In terms of DLQI total score, no significant improvement was obtained from moisturizer application 4 weeks after the start of radiation. However, 4 weeks after the start date, the change of DLQI total score was improved by moisturizer application in high D max cases. PO-0927 Assessing the Quality of Care in Breast Cancer Radiotherapy PO-0928 Safety and efficacy of concomitant RT and CDK4/6 inhibitors in metastatic breast cancer patients. L. Visani 1 , C. Saieva 2 , I. Desideri 1 , V. Scotti 1 , L. Dominici 1 , E. Scoccimarro 1 , M. Aquilano 1 , C. Cerbai 1 , V.E. Palmieri 3 , V. Maragna 1 , C. Becherini 1 , M. Bernini 4 , L. Sanchez 4 , L. Orzalesi 4 , J. Nori 5 , L. Antonuzzo 3 , S. Bianchi 6 , I. Meattini 1 , L. Livi 1 1 University of Florence, Department of Experimental and Clinical Biomedical Sciences, Florence, Italy ; 2 Cancer Research and Prevention Institute, Molecular and Nutritional Epidemiology Unit, Florence, Italy ; 3 Azienda Ospedaliero-Universitaria Careggi, Medical Oncology Unit, Florence, Italy ; 4 Azienda Ospedaliero-Universitaria Careggi, Breast Surgery Unit, Florence, Italy ; 5 Azienda Ospedaliero-Universitaria Careggi, Diagnostic Senology Unit, Florence, Italy ; 6 University of Florence, Pathology Unit, Florence, Italy Purpose or Objective Cyclin-dependent kinase 4/6 inhibitors (CDK4/6i), in combination with endocrine therapy (ET), currently represent the standard of care for I-II line metastatic hormonal receptor (HR)-positive HER2-negative breast cancer, demonstrating a significant improvement in terms Abstract withdrawn